Pioneers in unique disease-modifying technology
ActoBio Therapeutics™ is pioneering a new class of therapeutic agents called ActoBiotics® - targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics to treat a range of disorders, including immune-related diseases.

ActoBiotics® are based on the safe food-grade bacterium, Lactococcus lactis , which is used in the production of cheeses and other foods. L. lactis is designed and engineered to produce specific therapeutic agents for delivery directly to the relevant tissue, thus creating therapeutic applications across many diseases. This approach holds the promise for safer and more efficacious treatments than injectable agents.

ActoBio Therapeutics™ has a strong R&D pipeline with the latest stage candidate in Phase IIb, and an extensive portfolio of candidates ready for clinical development across a number of potential indications.

ActoBio Therapeutics™ is a wholly owned subsidiary of Intrexon Corporation (NYSE: XON).
executive team
PIETER ROTTIERS, PhD
Chief Executive Officer, Director
LOTHAR STEIDLER, PhD
Chief Technology Officer
LUC VAN FRAEYENHOVEN
Chief Financial Officer
STEFAN HERDINIUS, MSc, MBA
VP and Head of Strategic Drug Development